Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1175 of 2026 entries
View as:

A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00106548 Org: User:
Start: - End: 10/31/07 Due: 10/31/08

A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

Phase: N/A Priority: Normal
NCT ID: NCT01057667 Org: User:
Start: 02/28/10 End: 04/30/12 Due: 04/30/13

A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology

Phase: N/A Priority: Normal
NCT ID: NCT02204345 Org: User:
Start: 10/31/14 End: 03/31/16 Due: 03/31/17

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor

Phase: N/A Priority: Normal
NCT ID: NCT02079532 Org: User:
Start: 11/30/06 End: 11/30/10 Due: 11/30/11

A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00964704 Org: User:
Start: 03/31/11 End: 08/31/13 Due: 08/31/14

A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00087620 Org: User:
Start: 09/30/04 End: 10/31/04 Due: 10/31/05

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Phase: N/A Priority: Normal
NCT ID: NCT02861014 Org: User:
Start: 09/09/16 End: 12/15/20 Due: 12/15/21

An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice

Phase: N/A Priority: Normal
NCT ID: NCT02552940 Org: User:
Start: 10/31/15 End: 10/23/17 Due: 10/23/18

A Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01143740 Org: User:
Start: 06/30/10 End: 03/31/11 Due: 03/31/12

A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00796107 Org: User:
Start: 01/28/09 End: 03/03/10 Due: 03/03/11

A Dose-Escalating Study of RO4987655 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00817518 Org: User:
Start: 01/31/09 End: 12/31/14 Due: 12/31/15

A Study of RO6799477 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01893437 Org: User:
Start: 07/31/13 End: 10/31/13 Due: 10/31/14

Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population

Phase: N/A Priority: Normal
NCT ID: NCT02000531 Org: User:
Start: 01/31/14 End: 12/31/14 Due: 12/31/15

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Phase: N/A Priority: Normal
NCT ID: NCT03467373 Org: User:
Start: 03/13/18 End: 12/02/24 Due: 12/02/25

A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05661578 Org: User:
Start: 05/04/23 End: 09/30/25 Due: 09/30/26

A Study of CellCept (Mycophenolate Mofetil) Combined With Tacrolimus and Corticosteroids in Kidney Transplant Patients.

Phase: N/A Priority: Normal
NCT ID: NCT00758602 Org: User:
Start: 09/30/08 End: 02/28/11 Due: 02/28/12

A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6

Phase: N/A Priority: Normal
NCT ID: NCT03255096 Org: User:
Start: 08/28/17 End: 07/03/19 Due: 07/03/20

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

Phase: N/A Priority: Normal
NCT ID: NCT06965413 Org: User:
Start: 05/05/25 End: 09/20/27 Due: 09/20/28

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B

Phase: N/A Priority: Normal
NCT ID: NCT00922207 Org: User:
Start: 05/07/10 End: 09/29/14 Due: 09/29/15

A Study of Avastin (Bevacizumab) in Combination With Docetaxel and Cisplatin in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00661778 Org: User:
Start: 07/31/07 End: 07/31/11 Due: 07/31/12

An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)

Phase: N/A Priority: Normal
NCT ID: NCT03289182 Org: User:
Start: 09/15/17 End: 10/27/20 Due: 10/27/21

PRM-151 in the Prevention of Scarring Following Trabeculectomy

Phase: N/A Priority: Normal
NCT ID: NCT01064817 Org: User:
Start: 06/14/10 End: 11/14/12 Due: 11/14/13

A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD)

Phase: N/A Priority: Normal
NCT ID: NCT01793441 Org: User:
Start: 09/30/13 End: 09/30/16 Due: 09/30/17

A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy

Phase: N/A Priority: Normal
NCT ID: NCT04265261 Org: User:
Start: 06/05/20 End: 07/19/23 Due: 07/19/24

A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations

Phase: N/A Priority: Normal
NCT ID: NCT01153984 Org: User:
Start: 06/30/11 End: 07/31/15 Due: 07/31/16